https://www.selleckchem.com/pr....oducts/apo866-fk866.
treatment and at the end of the follow-up, suggesting better tolerance in the curcumin group. CONCLUSIONS Overall, treatment with curcumin in combination with paclitaxel was superior to the paclitaxel-placebo combination with respect to ORR and physical performance after 12 weeks of treatment. Intravenously administered curcumin caused no major safety issues and no reduction in quality of life, and it may be beneficial in reducing fatigue. ADVANCES IN KNOWLEDGE This is the first clinical study to explore the efficacy and safety of